CPC A61K 9/51 (2013.01) [A61K 9/127 (2013.01); A61K 9/1275 (2013.01); A61K 31/12 (2013.01); A61K 31/137 (2013.01); A61K 31/19 (2013.01); A61K 31/546 (2013.01); A61K 31/7034 (2013.01); A61K 31/713 (2013.01); A61K 38/14 (2013.01); A61K 38/28 (2013.01); A61K 39/29 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01)] | 20 Claims |
1. A method of treating a patient or subject in need of treatment of a disease state or condition comprising administering to said patient or subject a composition comprising one or more active molecules encapsulated in a liquid vesicle to provide an intact loaded vesicle wherein the outer surface coating of said loaded vesicle comprises at least one cholesteryl ester obtained from cholesterol and a C6-C26 fatty acid, said molecules obtaining in an effective amount an intracellular concentration in target cells of said patient or subject which is at least 2-fold greater than the concentration obtained by said molecules in the absence of said coating, wherein said molecules are selected from the group consisting of small molecules, proteins, monoclonal antibodies, peptides, polynucleotides, oligonucleotides, nucleic acids and mixtures thereof, wherein said administration includes at least one oral, parenteral or topical dosage form and said outer surface coating of said loaded vesicle remains intact during passage of said loaded vesicle across a membrane of a cell in said patient or subject and wherein said vesicle optionally releases said one or more molecules inside target cells by the action of cholesteryl ester hydrolases on said vesicle, and said disease state or condition is asthma, cancer, arthritis, Crohn's disease, multiple sclerosis, hyperlipidemia, obesity, type II diabetes, psoriasis, pulmonary arterial hypertension (PAH), inflammation, an intracellular viral, bacterial or fungal infection.
|